*Vueway is recommended at half the Gd dose vs. standard recommended dose of other currently approved GBCAs; for details on indications refer to locally approved SmPC.
Even with reduced Gd dose (0.05 mmol/kg), VUEWAY® offers non-inferior lesion visualization within multiple body areas vs. another macrocyclic GBCA at the standard recommended Gd dose (gadobutrol at 0.1 mmol/kg).1,2
References
1 VUEWAY® (gadopiclenol) SmPC, EMA, 10/2023.
2Kuhl C, Csőszi T, Piskorski W, et al. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-Enhanced Body MRI. Radiology. 2023;308(1):e222612.